[go: up one dir, main page]

Harer et al., 2021 - Google Patents

Novel Coronavirus disease 2019 (COVID-19) Current update: perspective on epidemiology, diagnosis, drug Targets and vaccines

Harer et al., 2021

View PDF
Document ID
7112125503037329837
Author
Harer S
Sonar P
Publication year
Publication venue
Coronaviruses

External Links

Snippet

Background: A novel coronavirus disease, 2019-nCoV (COVID-19), was reported first in Wuhan, the capital of Hubei, China, in late December 2019 and subsequently reached pandemic level affecting around 213 countries. As of 24th May 2020, the total number of …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/569Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
    • C12Q1/701Specific hybridization probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses

Similar Documents

Publication Publication Date Title
Ahn et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)
Pillay Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein
Hofmann et al. Cellular entry of the SARS coronavirus
Glowacka et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response
Focosi et al. Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy
Qian et al. Identification of the receptor-binding domain of the spike glycoprotein of human betacoronavirus HKU1
Park et al. Molecular basis of convergent evolution of ACE2 receptor utilization among HKU5 coronaviruses
Kumavath et al. The spike of SARS-CoV-2: uniqueness and applications
Dominguez et al. Isolation, propagation, genome analysis and epidemiology of HKU1 betacoronaviruses
Mahalingam et al. Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing
Catanzaro et al. ACE2 from Pipistrellus abramus bats is a receptor for HKU5 coronaviruses
Eggink et al. Phenotypic effects of substitutions within the receptor binding site of highly pathogenic avian influenza H5N1 virus observed during human infection
Ma et al. Dual-fluorescence labeling pseudovirus for real-time imaging of single SARS-CoV-2 entry in respiratory epithelial cells
Li et al. SARS-CoV-2 virology
Escalera et al. SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage
Kaur et al. COVID-19 infection: epidemiology, virology, clinical features, diagnosis and pharmacological treatment
Zhang et al. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies
Roessler et al. Quantitation of SARS-CoV-2 neutralizing antibodies with a virus-free, authentic test
Septisetyani et al. SARS-CoV-2 antibody neutralization assay platforms based on epitopes sources: live virus, pseudovirus, and recombinant S glycoprotein RBD
Zahn et al. Persistence of infectious SARS‐CoV‐2 particles for up to 37 days in patients with mild COVID‐19
Ren et al. Characterization of SARS-CoV-2 variants B. 1.617. 1 (Kappa), B. 1.617. 2 (Delta) and B. 1.618 on cell entry, host range, and sensitivity to convalescent plasma and ACE2 decoy receptor
Harer et al. Novel Coronavirus disease 2019 (COVID-19) Current update: perspective on epidemiology, diagnosis, drug Targets and vaccines
Vincenzi et al. The Fight against Human Viruses: How NMR Can Help?
Bhavaniramya et al. Comprehensive analysis of SARS-COV-2 drug targets and pharmacological aspects in treating the COVID-19
Vashisht et al. Exploring the immunodominant epitopes of SARS-CoV-2 nucleocapsid protein as exposure biomarker